Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Latanoprost

FDA-approved product (solution/drops, ophthalmic), marketed as Iyuzeh, Latanoprost, Xalatan and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Latanoprost
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Glaucoma
  • Hypertension
  • Ocular hypertension
  • Open-angle glaucoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Prostaglandin analogues
FDA pharmacologic class
Prostaglandin Analog FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA33.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli32.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Latanoprost in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Latanoprost with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Measuring the Effects of Netarsudil, Latanoprost, and Combination Therapy on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects

    NCT04401982 · start 2026-07-02

    Registered record
    Registry ID
    NCT04401982
    Conditions
    Ocular Hypertension; Suspect Glaucoma
    Interventions
    Rocklatan (Netarsudil 0.02%/ latanoprost 0.005); Latanoprost (0.005%)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-07-02
    Completion
    2027-03-17
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOcular Hypertension; Suspect Glaucoma
    InterventionRocklatan (Netarsudil 0.02%/ latanoprost 0.005); Latanoprost (0.005%)
    PhasePhase 4
    Registry statusRecruiting

  • Androgenic Alopecia TH07 Clinical Trial

    NCT07435012 · start 2026-04

    Registered record
    Registry ID
    NCT07435012
    Conditions
    Androgenic Alopecia
    Interventions
    TH07; TH07; Minoxidil 5% Topical Solution; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2026-04
    Completion
    2028-04
    Enrolment
    420

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAndrogenic Alopecia
    InterventionTH07; TH07; Minoxidil 5% Topical Solution; Placebo
    PhasePhase 3
    Registry statusRecruiting

  • Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma

    NCT07209410 · start 2025-11-01

    Registered record
    Registry ID
    NCT07209410
    Conditions
    Glaucoma
    Interventions
    Brimonidine Tartrate Ophthalmic 0.025%
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-11-01
    Completion
    2027-06-01
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma
    InterventionBrimonidine Tartrate Ophthalmic 0.025%
    PhasePhase 4
    Registry statusRecruiting

  • A Comparative Study of Intraocular Pressure Control Using Selective Laser Trabeculoplasty and Latanoprost as Initial Treatments for Primary Open Angle Glaucoma and Ocular Hypertension in Lagos State University Teaching Hospital

    NCT07310719 · start 2025-10-15

    Registered record
    Registry ID
    NCT07310719
    Conditions
    Primary Open Angle Glaucoma or Ocular Hypertension
    Interventions
    Selective laser trabeculoplasty; Latanoprost (0.005%)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-10-15
    Completion
    2026-11
    Enrolment
    138

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Open Angle Glaucoma or Ocular Hypertension
    InterventionSelective laser trabeculoplasty; Latanoprost (0.005%)
    PhaseNot applicable
    Registry statusRecruiting

  • Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction

    NCT07082816 · start 2025-09-02

    Registered record
    Registry ID
    NCT07082816
    Conditions
    Ocular Hypertension; Open Angle Glaucoma
    Interventions
    Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution; Netarsudil 0.02%/latanoprost 0.005% ophthalmic solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2025-09-02
    Completion
    2026-04-06
    Enrolment
    489

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOcular Hypertension; Open Angle Glaucoma
    InterventionNetarsudil 0.01%/latanoprost 0.005% ophthalmic solution; Netarsudil 0.02%/latanoprost 0.005% ophthalmic solution
    PhasePhase 3
    Registry statusCompleted

  • Study of Corneal Biomechanics in Glaucoma Patients Using Brillouin Microscopy

    NCT06993597 · start 2025-09-01

    Registered record
    Registry ID
    NCT06993597
    Conditions
    Glaucoma
    Interventions
    Prostaglandin Analogue -Containing IOP-Lowering Therapy; Beta Blocker; Brillouin Microscopy
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2025-09-01
    Completion
    2027-06
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma
    InterventionProstaglandin Analogue -Containing IOP-Lowering Therapy; Beta Blocker; Brillouin Microscopy
    PhaseNot recorded
    Registry statusRecruiting

  • Effect of IOP Lowering on Progressive HM

    NCT05850936 · start 2023-06-01

    Registered record
    Registry ID
    NCT05850936
    Conditions
    High Myopia; Intraocular Pressure
    Interventions
    Assigned Interventions: IOP-lowering eye drops
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Active not recruiting
    Start
    2023-06-01
    Completion
    2028-11-30
    Enrolment
    152

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHigh Myopia; Intraocular Pressure
    InterventionAssigned Interventions: IOP-lowering eye drops
    PhaseNot applicable
    Registry statusActive not recruiting

  • OPC-1085EL in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Chinese Subjects

    NCT05583474 · start 2022-09-27

    Registered record
    Registry ID
    NCT05583474
    Conditions
    Open Angle Glaucoma or Ocular Hypertension
    Interventions
    OPC-1085EL; 0.005% Latanoprost
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2022-09-27
    Completion
    2024-12-26
    Enrolment
    204

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen Angle Glaucoma or Ocular Hypertension
    InterventionOPC-1085EL; 0.005% Latanoprost
    PhasePhase 3
    Registry statusCompleted

  • A Comparative Confirmatory Study of STN1012600 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

    NCT05495061 · start 2022-08-09

    Registered record
    Registry ID
    NCT05495061
    Conditions
    Primary Open Angle Glaucoma, Ocular Hypertension
    Interventions
    STN1012600 ophthalmic solution 0.002%; Latanoprost ophthalmic solution 0.005%
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2022-08-09
    Completion
    2023-04-18
    Enrolment
    325

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Open Angle Glaucoma, Ocular Hypertension
    InterventionSTN1012600 ophthalmic solution 0.002%; Latanoprost ophthalmic solution 0.005%
    PhasePhase 3
    Registry statusCompleted

  • Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension.

    NCT04702789 · start 2021-10-19

    Registered record
    Registry ID
    NCT04702789
    Conditions
    Glaucoma, Open-Angle; Ocular Hypertension
    Interventions
    Dorzolamide-timolol-brimonidine and latanoprost; Dorzolamide-timolol and latanoprost
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2021-10-19
    Completion
    2023-11-23
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma, Open-Angle; Ocular Hypertension
    InterventionDorzolamide-timolol-brimonidine and latanoprost; Dorzolamide-timolol and latanoprost
    PhasePhase 4
    Registry statusTerminated

  • Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma

    NCT04405245 · start 2020-06-06

    Registered record
    Registry ID
    NCT04405245
    Conditions
    Ocular Hypertension; Primary Open Angle Glaucoma
    Interventions
    Latanoprost ophthalmic solution; AKB-9778 4%; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-06-06
    Completion
    2020-11-05
    Enrolment
    194

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOcular Hypertension; Primary Open Angle Glaucoma
    InterventionLatanoprost ophthalmic solution; AKB-9778 4%; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Nailfold Capillary Blood Flow With Latanoprost Bunod

    NCT03949244 · start 2019-08-15

    Registered record
    Registry ID
    NCT03949244
    Conditions
    Glaucoma, Open-Angle
    Interventions
    Latanoprost 0.005%; Latanoprost bunod 0.024%; Normal saline 0.9%; Nailfold capillaroscopy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-08-15
    Completion
    2020-10-01
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma, Open-Angle
    InterventionLatanoprost 0.005%; Latanoprost bunod 0.024%; Normal saline 0.9%; Nailfold capillaroscopy
    PhasePhase 4
    Registry statusCompleted

  • Comparison of Efficacy and Ocular Surface Disease Assessment Between Monoprost and BAK-preserved Latanoprost

    NCT04743622 · start 2019-04-30

    Registered record
    Registry ID
    NCT04743622
    Conditions
    Glaucoma; Ocular Hypertension
    Interventions
    Monoprost; Xalatan
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-04-30
    Completion
    2020-09-13
    Enrolment
    57

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma; Ocular Hypertension
    InterventionMonoprost; Xalatan
    PhasePhase 4
    Registry statusCompleted

  • Evaluating the Efficacy and Safety of Xalost S in Glaucoma Patients.

    NCT04164459 · start 2018-12-19

    Registered record
    Registry ID
    NCT04164459
    Conditions
    Glaucoma
    Interventions
    Xalost S; Xalatan; Taflotan-S
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2018-12-19
    Completion
    2020-02
    Enrolment
    144

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma
    InterventionXalost S; Xalatan; Taflotan-S
    PhasePhase 4
    Registry statusUnknown

  • CATS Tonometer IOP Reduction Latanoprost Verses Timolol

    NCT04178863 · start 2018-07-01

    Registered record
    Registry ID
    NCT04178863
    Conditions
    Glaucoma; Drugs
    Interventions
    CATS Tonometer; Latanoprost
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2018-07-01
    Completion
    2019-12-30
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma; Drugs
    InterventionCATS Tonometer; Latanoprost
    PhasePhase 4
    Registry statusUnknown